NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $45.00 at Ascendiant Capital Markets

NRx Pharmaceuticals (NASDAQ:NRXP) had its price objective raised by equities researchers at Ascendiant Capital Markets from $44.00 to $45.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

A number of other research analysts also recently weighed in on NRXP. EF Hutton Acquisition Co. I raised NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. HC Wainwright restated a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, November 25th.

NRx Pharmaceuticals Trading Up 1.6 %

Shares of NASDAQ:NRXP opened at $1.31 on Monday. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $7.33. The firm has a fifty day moving average price of $1.36 and a 200 day moving average price of $2.11. The stock has a market capitalization of $15.84 million, a PE ratio of -0.61 and a beta of 1.27.

Institutional Trading of NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Townsquare Capital LLC purchased a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned about 0.14% of NRx Pharmaceuticals as of its most recent SEC filing. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.